Pharma News, March 2017 Highlights Pill

FavoriteLoadingAdd to favorites
  • NPPA has alleged that the listed 634 drugs are being sold at prices higher than their ceiling price fixed by the Drug Price Control Order (DPCO). The list includes Pharma giants, Sun Pharmaceuticals, Lupin Pharma, Cipla, Cadila Healthcare and many more.
  • According to rating agency ICRA domestic pharmaceutical industry is likely to register moderate growth largely owing to increased regulatory scrutiny as well as consolidation of supply chain in the US market.
  • The Delhi High Court on allowed Indian drug manufacturers Natco Pharma and Alembic Pharmaceuticals to export Sorafinat and Rivaroxiban, generics of German pharma major Bayer’s own cancer and blood thinning medicines. The court held that the export of the pharmaceuticals were for informational and data gathering purposes and in line with the global Agreement on TRIPS
  • US FDA will lift the import alert imposed on the Sun Pharma Mohali (Punjab) manufacturing facility and remove the facility from official action initiated (OAI) status. This action clear the path for Sun Pharmato supply approved products from the Mohali facility to the US market.
  • USFDA issues warning letter to Mumbai-based Megafine Pharma for Vapi plant for violations of good manufacturing norms
  • Delhi-based pharmaceutical company Mankind Pharma is all set to make its foray into the diagnostic laboratories business with Pathkind. The Juneja family-promoted company wants to exploit the opportunity that Dr Lal PathLabs, Metropolis and SRL Diagnostics have tapped by making the sector more organised.
  • With a view to protect the brand value of Indian pharma and counter the allegations against Indian Pharma Industry as exporter of spurious/counterfeit drugs, bar coding has been made mandatory for the pharmaceutical exports (Formulations). Bar coding for pharmaceutical exports was made mandatory after conducting several stakeholders consultation and putting out public notices in advance, Commerce & Industry Minister Nirmala Sitharaman told Parliament.
  • Finding fault with the TDP government over the location of pharma units in the State, Public Accounts Committee (PAC) chairman and YSRC leader Buggana Rajendranath Reddy has said effluents released by the pharma units have an adverse impact on hatcheries.
  • Long-term performance is still impressive but the pharma funds have been extremely disappointing in the short-term. The pharma funds have returned 0.37 per cent in one week, 2.33 per cent in one month, -0.98 per cent in three months and -3.48 per cent in the last one year.
  • The pharmaceutical sector has produced the most number of ultra high net-worth individuals in India, accounting for almost 16 per cent of the total 132 wealthy Indians featured in the latest Hurun Global Rich List India report. There are 132 Indians enjoying a minimum networth of $1 billion and above. Out of this, 21 billionaires are from the pharma sector.
  • Drug pricing regulator NPPA has received Rs 672.28 crore fine till date from pharmaceutical companies for overcharging, Parliament was informed

Leave a Comment

Your email address will not be published. Required fields are marked *